HC Wainwright Has Pessimistic Outlook of BLFS Q2 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for shares of BioLife Solutions in a research report issued on Friday, May 29th. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will post earnings per share of ($0.02) for the quarter, down from their prior estimate of $0.01. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.09 per share. HC Wainwright also issued estimates for BioLife Solutions’ Q4 2026 earnings at $0.01 EPS, FY2026 earnings at $0.02 EPS and FY2027 earnings at $0.16 EPS.

BLFS has been the topic of a number of other research reports. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Monday, April 20th. Finally, Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $32.00.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $26.63 on Tuesday. The business’s 50 day simple moving average is $21.40 and its 200 day simple moving average is $22.84. BioLife Solutions has a 52-week low of $17.86 and a 52-week high of $29.62. The firm has a market cap of $1.30 billion, a PE ratio of -332.83 and a beta of 2.00.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%.The business had revenue of $27.50 million for the quarter, compared to analyst estimates of $25.66 million.

Insiders Place Their Bets

In other news, insider Karen A. Foster sold 96,923 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the completion of the transaction, the insider owned 113,742 shares of the company’s stock, valued at approximately $2,291,901.30. The trade was a 46.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the transaction, the insider directly owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. This trade represents a 12.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,297,423 shares of company stock valued at $30,087,998 in the last three months. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently made changes to their positions in the stock. Global Retirement Partners LLC acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at about $30,000. Kemnay Advisory Services Inc. acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at about $35,000. Hantz Financial Services Inc. increased its stake in shares of BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 659 shares during the period. Quarry LP increased its stake in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 713 shares during the period. Finally, State of Wyoming bought a new stake in shares of BioLife Solutions during the 1st quarter valued at about $52,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.